Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse

Michael Fraser; Julie Livingstone; Jeffrey L. Wrana; Antonio Finelli; Housheng Hansen He; Theodorus van der Kwast; Alexandre R. Zlotta; Robert G. Bristow; Paul C. Boutros

doi:10.1038/s41467-021-26489-0

Nature Communications (Oct 2021)

Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse

Michael Fraser,
Julie Livingstone,
Jeffrey L. Wrana,
Antonio Finelli,
Housheng Hansen He,
Theodorus van der Kwast,
Alexandre R. Zlotta,
Robert G. Bristow,
Paul C. Boutros

Affiliations

Michael Fraser: Department of Surgery, Division of Urology, University of Toronto
Julie Livingstone: Department of Human Genetics, University of California
Jeffrey L. Wrana: Lunenfeld Research Institute, Mount Sinai Hospital
Antonio Finelli: Department of Surgery, Division of Urology, University of Toronto
Housheng Hansen He: Princess Margaret Cancer Centre
Theodorus van der Kwast: Department of Laboratory Medicine and Pathobiology, University of Toronto
Alexandre R. Zlotta: Department of Surgery, Division of Urology, University of Toronto
Robert G. Bristow: Department of Medical Biophysics, University of Toronto
Paul C. Boutros: Department of Human Genetics, University of California

DOI: https://doi.org/10.1038/s41467-021-26489-0
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 15

Abstract

Read online

Biomarkers of prostate cancer metastasis have been difficult to determine with confidence. Here the authors analyse mutation prevalence in 1844 prostate cancers and show that ZNRF3 loss is enriched in metastatic, castration-resistant prostate cancer and associated with metastasis of localized disease.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal